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Abstract
Over the past two decades, significant technological advances have facilitated the identification of hundreds of genes
associated with hearing loss. Variants in many of these genes result in severe congenital hearing loss with profound impli-
cations for the affected individual and their family. This review collates these advances, summarizing the current state of
genomic knowledge in childhood hearing loss. We consider how current and emerging genetic technologies have the
potential to alter our approach to the management and diagnosis of hearing loss. We review approaches being taken to
ensure that these discoveries are used in clinical practice to detect genetic hearing loss as soon as possible to reduce
unnecessary investigations, provide information about reproductive risks, and facilitate regular follow-up and early treatment.
We also highlight how rapid sequencing technology has the potential to identify children susceptible to antibiotic-induced
hearing loss and how this adverse reaction can be avoided.
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Introduction
In 1997, a team of researchers identiﬁed a large family
from the Mirpur region of Pakistan in which multiple
members were aﬀected by nonsyndromic hearing loss
(NSHL; Kelsell et al., 1997). Using linkage analysis
and Sanger sequencing, the authors identiﬁed a
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common pathogenic variant in GJB2, a gene, which
encodes a protein called connexin-26, that was respon-
sible for the hearing loss in this family. At the same time,
major sequencing facilities around the world were colla-
borating to methodically analyze the whole sequence of
the human genome. The Human Genome Project to
sequence a complete human genome had been formally
underway for 7 years but was not ﬁnished until 2003, at a
total cost of approximately $3 billion (Green, Watson, &
Collins, 2015). Just over 20 years since the discovery of
GJB2 as a cause of NSHL and 15 years since completion
of the Human Genome Project, the landscape of hearing
loss genetics has changed fundamentally. To date, over
100 genes have been associated with NSHL (https://her-
editaryhearingloss.org), and the capacity to identify
pathogenic variants in those genes has increased expo-
nentially. Both the speed of variant identiﬁcation and the
cost of DNA sequencing have improved dramatically;
genetic variants associated with hearing loss can now
be identiﬁed at the bedside in minutes and sequencing
a whole genome now costs less than $1,000.
Hearing loss aﬀects between 1 and 2 newborns per
1,000 and can have a signiﬁcant impact on a child’s com-
munication, quality of life, and educational attainment
(Roland et al., 2016; Teasdale & Sorensen, 2007; Wood,
Sutton, & Davis, 2015). As such, prompt recognition and
accurate diagnosis are crucial to optimize outcomes. The
etiology of hearing loss is manifold but can be typically
divided into either environmental or genetic causes. The
most prescient environmental exposures include neonatal
or prenatal infections, extreme prematurity, and expos-
ure to ototoxic agents, either during pregnancy or in the
neonatal period (C. C. Morton & Nance, 2006;
Robertson, Howarth, Bork, & Dinu, 2009).
Meanwhile, approximately 50% of all cases of neonatal
deafness are caused by an underlying genetic variant
(Smith, Bale, & White, 2005). Children might carry a
genetic variant resulting in NSHL or syndromic hearing
loss (SHL), or they might harbor a genetic variant that
predisposes to drug-induced ototoxicity.
In cases of SHL or NSHL, early identiﬁcation and
conﬁrmation of the genetic variant facilitates patient
management. If a patient is found to harbor a variant
in a gene associated with NSHL, the family can be coun-
seled accordingly, and management can focus on the
auditory system. If the gene, or even the speciﬁc variant,
is associated with syndromic disease, appropriate surveil-
lance can be initiated to monitor the development of
additional nonhearing-associated complications. This
appreciation of genotype–phenotype correlation is
increasingly allowing clinicians to develop personalized
management plans and more relevant genetic counseling
for patients and families (Parker & Lucassen, 2004).
Advances in sequencing capabilities and understanding
of the genome have begun to radically alter our ability to
identify and interpret genetic variants, leading tomore rapid
diagnosis, improved patient monitoring, and, in some cases,
avoidance of hearing loss. Here, we highlight the increasing
relevance of genetics in the diagnosis, management, and
prevention of hearing loss in the neonatal period.
Role of Genetic Testing in the Diagnosis of
Hereditary Hearing Impairment
Estimates have previously suggested that at least 1% of
all human genes encode a protein relating to hearing
function with varied roles pertaining to the morphogen-
esis or maintenance of structures in the auditory path-
way (Friedman & Griﬃth, 2003). Hearing loss can be
broadly classiﬁed as nonsyndromic, without extra-auri-
cular features, or SHL, where the phenotype can involve
a diverse range of body systems external to the auditory
pathway (Smith et al., 2005). NSHL is the most common
clinical presentation, accounting for 70% of congenital
cases (C. C. Morton & Nance, 2006).
Variants in hearing loss-associated genes can be inher-
ited in an autosomal-recessive, autosomal-dominant,
X-linked, or a mitochondrial pattern (Smith et al.,
2005). The aﬀected gene, or even the speciﬁc variant,
often correlates with a distinct clinical phenotype includ-
ing age of onset, phenotypic severity, disease progression,
and the auditory frequencies aﬀected (Snoeckx et al.,
2005; Taylor et al., 2013). The majority of prelingual
onset hearing loss follows an autosomal-recessive inherit-
ance, aﬀecting early speech development, whereas auto-
somal-dominant forms are more frequently associated
with postlingual deafness (Sloan-Heggen et al., 2016).
Accurate clinical phenotyping and a thorough family his-
tory can therefore be useful in establishing and reﬁning a
list of candidate genes. However, the relationship between
genotype and phenotype is not always consistent and
hearing loss disorders demonstrate signiﬁcant phenotypic
overlap (Hoefsloot, Feenstra, Kunst, &Kremer, 2014). In
addition, locus heterogeneity is a feature of certain syn-
dromes, meaning that some disorders can result from
variants in several genes, such as in Usher syndrome
(MIM 276900; Keats & Savas, 2004). Furthermore, vari-
ants in certain genes, for example, GJB2, are associated
with both dominantly and recessively inherited hearing
loss (Snoeckx et al., 2005). Because of this phenotypic
and genetic heterogeneity, clinical features and family his-
tory are rarely suﬃcient to predict the causative gene. This
has led to the development of gene panels as part of a
wider testing strategy, where a number of genes or genetic
variants can be assessed in a single assay.
Targeted Gene Panels
The British Association of Audiological Physicians
(BAAP, 2015) has produced guidelines for the etiological
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assessment of bilateral sensorineural hearing loss in chil-
dren (Figure 1). Level 1 investigations include the clinical
history and examination, audiograms of the family, oph-
thalmological assessment, cytomegalovirus (CMV) test-
ing, an electrocardiogram, brain imaging, urine analysis,
and testing for variants in GJB2. This initial screen is
designed to identify the most common causes of bilateral
hearing loss in childhood. The electrocardiogram is used
to screen for the presence of a prolonged QT interval,
indicative of Jervell and Lange-Nielsen syndrome (MIM
220400), whereas proteinuria might suggest a diagnosis of
Alport’s syndrome (MIM 301050). Ophthalmological
assessment can reveal a number of abnormalities, which
can indicate syndromic diseases such as Usher (MIM
276900), CHARGE (MIM 214800), or Waardenburg
(MIM 193500) syndromes. Although these extra-auricu-
lar features can be extremely useful in helping to establish
a diﬀerential diagnosis, their absence has the potential to
be misleading in determining a precise diagnosis. The
characteristic coloboma of CHARGE syndrome is
absent in approximately 20% of patients, while the pro-
teinuria in Alport’s syndrome is progressive, meaning this
feature will often be absent in younger patients (Trider,
Arra-Robar, van Ravenswaaij-Arts, & Blake, 2017).
Due to the prevalence of GJB2 variants in NSHL,
GJB2 testing is included in Level 1 investigations, but
no other genes are assessed at this level. If no etiological
cause is identiﬁed from the Level 1 testing, progression to
Level 2 testing includes consideration of microarray
comparative genomic hybridization to identify chromo-
somal alterations, including deletions and duplications
and single gene testing for variants in SLC26A4
(MIM 605646), EYA1 (MIM 601653), and OTOF
(MIM 603681), the respective causes of Pendred (MIM
274600) and branchiootorenal (MIM 113650) syndromes
and autosomal-recessive auditory neuropathy (MIM
601071). If the child or the mother has been exposed to
aminoglycoside antibiotics, then testing for the
m.1555A>G variant is appropriate as this variant is
associated with aminoglycoside-related ototoxicity. If
these further investigations fail to reveal the cause of
the hearing loss, further genetic testing, often using a
gene panel-based approach, can be performed.
Most modern gene panels utilize next-generation
sequencing technology, a catch-all term for a range of
approaches that allow for massively parallel high-
throughput sequencing, providing results signiﬁcantly
quicker than traditional methods (Table 1). Targeted
panels typically constrain their sequencing to a prede-
ﬁned set of genes, decided upon by the operator. There
are a number of commercially available panels, which
vary in their methodology and in the number of genes
targeted (Sloan-Heggen & Smith, 2016). Since 2001, the
UK Genetic Testing Network (n.d.) has published the
NHS Directory for Diagnostic Testing, which evaluates
and recommends genetic tests commissioned in the NHS.
At present in the United Kingdom, an inherited hearing
loss genetic panel has been approved to analyze the
coding regions and intron/exon boundaries of 95 genes.
Conﬁrmatory testing of any variant identiﬁed is then
performed via Sanger sequencing to facilitate testing in
other family members.
As new disease-causing genes are discovered and vali-
dated, they can be included in existing hearing loss gene
panels. The OtoSCOPE gene panel (University of Iowa
Figure 1. The British Association of Audiological Physicians has
produced guidelines for the etiological assessment of bilateral
sensorineural hearing loss in children. The left side of the sche-
matic demonstrates the current stepwise testing strategy of a child
with hearing loss via Level 1 and Level 2 tests in this guideline. The
right side of the schematic displays how emerging genetic tech-
nologies might be implemented in future testing strategies. Note.
ECG ¼ electrocardiogram; WES ¼ whole exome sequencing;
POCT ¼ Point of care Test; AIHL ¼ Antibiotic Induced Hearing
Loss; USS ¼ Ultrasound Scan; WGS ¼ Whole Genome
Sequencing.
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Hospitals and Clinics, Iowa, USA) was evaluated in
1,119 individuals and found to have an overall diagnostic
rate of 39% (Shearer et al., 2010; Sloan-Heggen et al.,
2016). Importantly updated versions of the panel have
resulted in an increased diagnostic rate of 2%. This itera-
tive process highlights some key disadvantages of gene
panels: the genes assessed are often not a contemporan-
eous list, there is no scope for novel gene discovery, and,
crucially from a clinical perspective, samples where a
molecular diagnosis is not achieved will have to be
rerun every time there is an update to the panel or new
causative genes are identiﬁed. Whole exome and whole
genome sequencing (WES and WGS, respectively)
approaches circumnavigate these issues as all genes are
sequenced. In WES, the entire protein coding part of the
genome, representing approximately 2% of the total
sequence is captured (Sloan-Heggen et al., 2016). These
data can then be stored securely and reanalyzed as new
disease-causing genes and disease variants are identiﬁed.
Whole Genome Sequencing
The BAAP guidelines in 2015 acknowledged that wide-
spread genetic testing for deafness is likely to become
Table 1. A Comparison of Different Genetic Testing Strategies.
Testing method Details Advantages Disadvantages
Targeted gene panels
Sequences a curated panel of genes
related to hearing loss, typically
via next-generation sequencing
Timeframe: Weeks
Cost: (£800)
Clinically available
1. Targets most relevant (high
yield) hearing loss genes
2. Relatively quick turnaround
compared with other
strategies
1. Variants in genes not on the
panel are not identified
2. Intronic variants will not be
identified
3. As new hearing loss genes are
identified; negative samples
will have to be reanalyzed
4. Limited detection of copy
number and structural
variants
Whole exome sequencing
Using next-generation sequencing,
the whole protein coding region
of the genome (exome) is
sequenced
Timeframe: Weeks–Months
Cost: (variable <£1, 000)
Not routinely available
1. Potential to identify variants in
any protein coding gene
2. Allows for iterative reanalysis
of data as relevant genes are
identified
1. Causative intronic variants
may be missed
2. Requires more complex bio-
informatic analysis after
sequencing
3. Limited clinical availability in
the United Kingdom
4. Limited detection of copy
number and structural vari-
ants
5. Ethical issues of secondary
findings
Whole genome sequencing
Using next-generation sequencing,
the whole genome (protein and
non-protein coding) is sequenced
Timeframe: Weeks–Months
Cost: (to be decided)
Available in United Kingdom
from 2019
1. Potential to identify both
intronic and exonic variants
2. Allows for iterative reanalysis
of data as relevant genes are
identified
3. Facilitates copy number and
structural variation
identification
1. Requires complex data hand-
ling after sequencing
2. Remains expensive
3. Ethical issue of secondary
findings
Microarray ‘‘DNA’’ chips
A platform designed to rapidly
identify whether known variants
are present in a particular
sample
Timeframe: Hours
Cost: (<£50)
Not in routine clinical practice
1. Rapid result available within
the same day
2. Relatively inexpensive
3. Targets most relevant (high
yield) hearing loss variants
1. Variants not in the assay will
not be identified
2. Different assay designs will be
required for different
populations
Point of care genetic testing
Testing which provides the clinician
with a rapid genetic result
Timeframe: Minutes
Cost: (to be decided)
Clinical trial ongoing
1. Rapid turnaround of result
2. Can be performed at bedside
by health-care workers
3. Potential to avoid aminogly-
coside-induced hearing loss
1. Currently only has specific
use-cases in avoiding hearing
loss (m.1555A>G)
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available with the implementation of next-generation
sequencing, where large numbers of genes can be
sequenced rapidly and cost-eﬀectively. As such, guide-
lines for further genetic testing are likely to evolve in
coming years and genetic testing will become increasingly
accessible earlier in the diagnostic process. In 2018, the
NHS National Genomics Service was launched creating
a genomic laboratory service with a national genomic
test directory to promote accessible, equitable, and
cost-eﬀective genetic testing across England. When
fully operational, this will facilitate comprehensive
access to genetic testing for individuals, especially chil-
dren, with NSHL.
WGS encompasses both coding and noncoding
regions, including the other 98% of the genome not cap-
tured by WES (Table 1). These noncoding (intronic)
regions were historically considered junk DNA, with
little relevance other than as a place holder for the pro-
tein coding exons (Franchini & Pollard, 2017). It is now
understood that these intronic regions have vital roles
and that noncoding variants can lead to disease
(Check, 2006). In a consanguineous family from Saudi
Arabia with a clinical diagnosis of Usher syndrome,
standard genetic testing failed to reveal a causative vari-
ant in any of the associated genes. WGS meanwhile iden-
tiﬁed a deep intronic variant, which created a cryptic
splice site causing loss of protein resulting in the pheno-
type (Khan et al., 2017). Cases such as this highlight the
relevance of WGS and its additional diagnostic value
beyond WES or panels. Eﬀorts to introduce WGS into
clinical practice have been supported by initiatives such
as the 100,000 Genomes Project in the United Kingdom
and the SEQuencing a Baby for an Optimal Outcome
trial in the United States (C. Morton, 2015). This project
is currently underway at the Brigham and Women’s
Hospital and aims to establish the eﬃcacy of performing
WGS in all babies who fail their newborn
screening assessment. Considering the falling cost of
sequencing alongside the current enthusiasm for this
approach, it is foreseeable that WGS will become stand-
ard of care for individuals with severe to profound hear-
ing loss after negative Level 1 and Level 2 investigations
(Figure 1).
Rapid Genetic Sequencing
The utilization and impact of genetic information, by the
very nature of sequencing technology, have always been
in the context of diagnosing chronic diseases such as rare
syndromic disorders and cancers. Time between sample
collection and delivery of a clinically relevant result is
often measured in months rather than minutes. The con-
cept that genetic information might be generated in real
time and inﬂuence treatment decisions, especially in the
acute setting, has been infeasible. However, novel
sequencing approaches have been developed in recent
years and have the potential to provide clinically action-
able results in a clinically relevant timeframe.
Microarray Chip-Based Sequencing
In parallel to advances in WGS and WES, chip-based
microarray technology has become increasingly avail-
able. These generate data that are often straightforward
to interpret, rapid to undertake, and are cost-eﬀective.
Although there are over 100 disease-causing genes asso-
ciated with congenital hearing loss, speciﬁc variants
within certain genes account for a larger proportion of
cases. The GJB2 c.35delG variant is common across
Western Europe causing an estimated 75% of all
GJB2-related NSHL, while the SLC26A4 p.Leu236Pro
(c.707T>C) and the p.Thr416Pro (c.1246A>C) variants
are also widely prevalent across the same regions, caus-
ing 23.1% and 12.8% of all SLC26A4-related deafness in
the United Kingdom (Tsukada, Nishio, Hattori, &
Usami, 2015). Targeted assays can now be developed
to cheaply and rapidly identify speciﬁc variants,
common within a population. The CapitalBio-Miami-
Oto-Array (CapitalBio Corporation, Beijing, China)
has been designed, using microﬂuidic technology, to
identify nine of the most common variants in patients
of European descent within four disease-causing genes,
GJB2, GJB6, SLC26A4, and the mitochondrial gene,
RNR1 (Yan et al., 2017). This technology facilitates an
initial screen of the most common genetic causes of
NSHL for less than $30 in approximately 4 hr.
Targeted variant genotyping could well form part of
an updated BAAP guideline as a new Level 1 investiga-
tion. Alternatively, this approach might be considered as
part of newborn screening program as a supplement to
the newborn hearing test, where genotyping would be
undertaken on blood spots from all babies. Potentially,
this would identify newborns that pass the newborn
hearing screen but are at an increased risk of child-
hood-onset NSHL and so should undergo more regular
assessment and earlier intervention (Figure 1). A formal
health economic evaluation and determination of accept-
ability and feasibility would be required for implementa-
tion of this technology but given low cost and rapid
turnaround, this requires serious consideration.
It is important to consider ethnic variation when
designing targeted variant panels to be used more
widely for the investigation of hearing loss. Although
the GJB2 c.35delG variant is common across Western
Europe, its prevalence is negligible across India, China,
and across Southeast Asia. Instead, these ethnic groups
have diﬀerent common genetic variants associated with
hearing loss (Tsukada et al., 2015). The vast majority of
genomes sequenced to date are from individuals of White
European descent. This means that the genetic
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knowledge of certain disorders may be less mature or
even not relevant in other populations. There are now
international eﬀorts to diversify genomic datasets by
sequencing genomes from greater numbers of individuals
without European ancestry. When designing chip-
based assays for hearing loss, it is important to consider
population diversity and several diﬀerent population-
speciﬁc chips may be required to ensure appropriate
coverage.
Point of Care Testing
Many commonly prescribed medications have the poten-
tial to cause ototoxicity, particularly if dispensed over a
protracted period or in excess. Aminoglycosides are
broad-spectrum antibiotics, which act by binding to the
16S rRNA component of the bacterial 30S ribosomal
subunit, resulting in the translation of truncated proteins
(Lanvers-Kaminsky & Ciarimboli, 2017; Schacht,
Talaska, & Rybak, 2012). These abnormal proteins
stimulate a stress response within the bacteria culminat-
ing in cell death. Due to their low cost and eﬀectiveness,
they are one of the most frequently prescribed medicines
globally, used in cases of Gram-negative sepsis, pseudo-
monas colonization, and treatment of multidrug-resis-
tant tuberculosis (Bitner-Glindzicz & Rahman, 2007).
The National Institute for Health and Care Excellence
(NICE) advises the use of intravenous benzylpenicillin
with gentamicin as the ﬁrst-choice antibiotic regimen
for empirical treatment of suspected infection in the neo-
natal period (NICE CG149). This combination has the
major advantage of having a narrow spectrum of activity
and lower risk of antibiotic resistance compared to alter-
native antibiotic regimens.
The side eﬀect proﬁle of aminoglycoside antibiotics is
well known, with nephrotoxicity, vestibulotoxicity, and
ototoxicity commonly recognized in cohorts who receive
large amounts of aminoglycoside (Prayle & Smyth,
2010). Careful analysis revealed that aminoglycoside-
induced ototoxicity clusters within families and this
trait was transmitted maternally, consistent with mito-
chondrial inheritance. Further work demonstrated that
this susceptibility was caused by a variant in the 12S
rRNA (RNR1) m.1555A>G (Prezant et al., 1993).
This variant causes a change in the conformation of
the 12S rRNA, producing a structure more similar to
the bacterial 16S rRNA.
The m.1555A>G variant is strongly associated with
aminoglycoside-induced ototoxicity and has a reported
prevalence of 0.2% (1 in 500). As part of a wider
study, we accessed data from 119,845 individuals within
the U.K. Biobank dataset, establishing a U.K. wide preva-
lence of 0.198% (95% conﬁdence interval: 0.173%–
0.225%) for the variant. It has previously been suggested
that genetic testing should be used in children requiring
aminoglycosides to prevent hearing loss and that this
approach would be cost-eﬀective when balanced against
the costs of lifelong deafness (Bitner-Glindzicz et al.,
2009; Bitner-Glindzicz & Rahman, 2007). Currently, in
many centers, patients with cystic ﬁbrosis are tested for
the variant preemptively as it is anticipated that these indi-
viduals will require aminoglycoside antibiotics to treat
Gram-negative respiratory infections at some stage
during their illness. This is currently undertaken using pyr-
osequencing, which takes up to 7 days to return a result
from the laboratory. Understandably, this approach is not
suitable for use in neonates with suspected sepsis where a
prescribing decision is required within an hour.
At present, there is an inability to test for the
m.1555A>G variant in the acute setting such as babies
admitted to the neonatal intensive care unit, representing
approximately 90,000 admissions per year in the
United Kingdom alone. Based on the prevalence of the
variant, approximately 180 cases of deafness could
be avoided per year, if clinicians were able to identify car-
riers and prescribe an alternatively eﬃcacious antibiotic
regimen. We have developed a loop-mediated isothermal
ampliﬁcation assay for buccal swabs on a point-of-need
rapid thermocycler platform, which can identify the
m.1555A>G variant in 22 min (Duﬀy et al., 2017).
The Pharmacogenetics to Avoid Loss of Hearing trial
has been designed to determine the feasibility of imple-
menting this assay in the acute setting. This represents
the ﬁrst study where a genetic test is being used to impact
patient management in this context. Over a 6-month
period, every admission to two large neonatal intensive
care units in Manchester and Liverpool will receive this
genetic test on admission to the neonatal intensive care
unit and antibiotic prescribing will be tailored depending
on the presence or absence of the variant.
Studies such as this serve to demonstrate a dramatic
shift in our ability to leverage the power of genetics in
everyday healthcare. By utilizing a novel genetic technol-
ogy, we can now deliver a clinically relevant genetic
result within a clinically relevant timeframe, avoiding a
major cause of neonatal ototoxicity in the acute setting.
Conclusions
Over the past two decades, marked advancements in gen-
etic technologies have facilitated our appreciation of
the rich genetic variation underpinning childhood
hearing loss. Next, we must ensure the equitable and com-
prehensive introduction of clinical genomic testing allow-
ing early diagnosis and facilitating optimum clinical care.
In some cases, such as by avoiding adverse drug reactions,
adoption of rapid genetic screening may prevent certain
forms of hearing loss completely. The approaches will
develop as technologies improve, costs alter, and diﬀerent
treatment options become available.
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